Treatment options for relapsed and refractory multiple myeloma

Area of Science:

• Hematology
• Oncology
• Clinical Therapeutics

Background:

• Significant advancements in multiple myeloma patient outcomes have been achieved over recent decades.
• Current treatments include approved antimyeloma agents and autologous stem cell transplantation.
• The development of targeted agents has led to complex and heterogeneous treatment patterns for relapsed myeloma.

Purpose of the Study:

• To describe an evidence-based approach for managing relapsed multiple myeloma.
• To identify key factors to consider when treating patients with relapsed disease.
• To discuss emerging targeted agents and therapeutic targets for achieving durable remissions.

Main Methods:

• Review of current literature and clinical guidelines.
• Analysis of treatment patterns in relapsed multiple myeloma.
• Discussion of novel therapeutic agents and targets in development.

Main Results:

• Treatment of relapsed multiple myeloma is complex, with considerable variation in therapeutic strategies.
• Consensus on treatment initiation timing, agent selection, and the role of transplant in relapse is lacking.
• Newer agents and targets are under investigation to improve patient outcomes.

Conclusions:

• An evidence-based approach is crucial for managing relapsed multiple myeloma.
• Careful consideration of patient-specific factors and emerging therapies is necessary.
• The goal of treatment is to achieve durable remissions in patients with relapsed multiple myeloma.